Monte Rosa Therapeutics, Inc. (GLUE) Profit Margins
Over the twelve months to 2026-06-30, Monte Rosa Therapeutics, Inc. (GLUE) had operating margin -633.0%, net margin -560.9%, free cash flow margin -111.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GLUEMonte Rosa Therapeutics, Inc.Follow GLUE — free
—
Price chart with a free account
- Market cap
- 924.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating margin | -107.3% | -43.8% | -633.0% | |
| Net margin | -96.1% | -31.2% | -560.9% | |
| FCF margin | 50.3% | -22.2% | -111.7% |
USD millions · SEC XBRL
Monte Rosa Therapeutics, Inc. — questions
- What is Monte Rosa Therapeutics, Inc.'s operating margin?
- -633.0% over the twelve months to 2026-06-30.
- What is Monte Rosa Therapeutics, Inc.'s net profit margin?
- -560.9% over the twelve months to 2026-06-30.
Every figure on this page comes from Monte Rosa Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.